Table 2 Clinicopathological characteristics of 225 patients with NPC.
Variables | Low FARI (%) | High FARI (%) | P value |
|---|---|---|---|
Age | |||
 ≤ 60 | 107 (89.9%) | 89 (84%) | 0.129 |
 > 60 | 12 (10.1%) | 17 (16%) | |
Sex | |||
 Male | 92 (77.3%) | 70 (66%) | 0.074 |
 Female | 27 (22.7%) | 36 (34%) | |
ECOG PS | |||
 0 | 83 (69.7%) | 50 (47.2%) | 0.003 |
 1 | 35 (29.4%) | 54 (50.9%) | |
 2 | 1 (0.8%) | 2 (1.9%) | |
BMI | |||
 < 18.5 | 11 (9.2%) | 8 (7.5%) | 0.497 |
 18.5–24 | 48 (40.3%) | 51 (48.1%) | |
 ≥ 24 | 60 (50.4%) | 47 (44.3%) | |
EBV-DNA (n = 142) | |||
 < 400 | 51 (64.6%) | 30 (47.6%) | 0.043 |
 ≥ 400 | 28 (35.4%) | 33 (52.4%) | |
T stage | |||
 1–2 | 77 (64.7%) | 40 (37.7%) |  < 0.001 |
 3–4 | 42 (35.3%) | 66 (62.3%) | |
N stage | |||
 0–1 | 36 (30.3%) | 21 (19.8%) | 0.072 |
 2–3 | 83 (69.7%) | 85 (80.2%) | |
Clinical stage | |||
 II | 22 (18.5%) | 12 (11.3%) |  < 0.001 |
 III | 82 (68.9%) | 50 (47.2%) | |
 IVa | 15 (12.6%) | 44 (41.5%) | |
Treatment | |||
 CCRT | 82 (68.9%) | 72 (67.9%) | 0.887 |
 Non-CCRT | 37 (31.1%) | 34 (32.1%) | |
